NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan A. Jacoby, Jeffrey E. Lancet, Gabriel N. Mannis, Guido Marcucci, Michael G. Martin, Alice S. Mims, Jadee Neff, Reza Nejati, Rebecca L. Olin, Mary‐Elizabeth M. Percival, Thomas Prébet, Amanda Przespolewski, Dinesh S. Rao, Farhad Ravandi‐Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew J. Wieduwilt, Kristina M. Gregory, Ndiya Ogba, Martin S. Tallman, Alison Walker, Eunice Wang, Ajibola Awotiwon, Sydney L. Roth, Katie Stehman
Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States.1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel's most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.